Compare FuelCell Energy Inc (FCEL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Repligen Corporation Common Stock — how do they compare? FuelCell Energy Inc trades at $14 (market cap $1.24B), while Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 9× FuelCell Energy Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, FuelCell Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Repligen Corporation Common Stock for 0 Days on average.
| FCEL | RGEN | |
|---|---|---|
Market Cap | $1.24B | $11.14B |
Volume | 7,483,477 | 1,259,263 |
Sector | Industrials | Health |
52-Week High | $36.01 | $194.57 |
52-Week Low | $6.00 | $102.87 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $818.79M | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $14.16, down 13.5% over 24 hours, reflecting negative momentum amid ongoing operational losses. The stock exhibits a bearish technical signal, with key support at $14. Recent financials show revenue of $158.16M in 2025 but a net loss of $187.90M, with negative gross and net income margins. Analyst consensus is split evenly between Buy and Hold, with a $21.57 price target. Multiple law firms have announced securities class actions related to disclosures from June to September 2026, adding legal overhangs.
FCEL's outlook remains challenged by persistent unprofitability and cash burn, though analyst targets suggest potential upside from current levels. Key risks include the class action lawsuits, execution on scaling power agreements, and the company's ability to achieve positive cash flow. The stock presents a high-risk opportunity contingent on operational turnaround and resolution of legal issues.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
